Pyxis Oncology (PYXS) Operating Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Operating Expenses data on file, last reported at $29.3 million in Q4 2025.

• Operating Expenses for Q4 2025 came in at $29.3 million, down 26.79% year-over-year; the trailing twelve-month figure through Dec 2025 was $98.3 million (down 6.94% YoY), and the FY2025 annual result was $98.3 million, down 6.94% from the prior year.
• Operating Expenses advanced to $29.3 million in Q4 2025 per PYXS's latest filing, from $23.5 million in the prior quarter.
• Over five years, Operating Expenses peaked at $40.1 million in Q4 2024 and troughed at $5.9 million in Q2 2021.
• A 5-year average of $24.0 million and a median of $23.2 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 333.02% in 2022, then plunged 53.21% in 2023.
• A 5-year view of Operating Expenses shows it stood at $16.4 million in 2021, then jumped by 131.18% to $38.0 million in 2022, then sank by 53.21% to $17.8 million in 2023, then jumped by 125.52% to $40.1 million in 2024, then dropped by 26.79% to $29.3 million in 2025.
• Business Quant data shows PYXS's Operating Expenses at $29.3 million in Q4 2025, $23.5 million in Q3 2025, and $22.6 million in Q2 2025.